HLB Genex announced on the 10th that it will acquire 1,316,005 shares of Anigen, a peptide bio-material and global innovative new drug development company, for approximately 8 billion KRW.
After the stock acquisition, HLB Genex's stake in Anigen will be 14.2%. The scheduled date for the stock acquisition is the 19th.
HLB Genex stated that the purpose of this stock acquisition is to "secure business competitiveness by creating synergy with existing businesses."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
